FDA Brief

Warning letters Drugs

FDA warning letter to

Sensory Cloud, Inc

High riskIssued Apr 6, 2022Posted Apr 7, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warn Sensory Cloud that its FEND nasal mister is an unapproved, misbranded drug sold with COVID-19 prevention and treatment claims.

What happened

FDA reviewed hellofend.com on March 14, 2022, and FTC reviewed it on April 4, 2022; FDA also reviewed Facebook and Instagram pages that direct consumers to the site. FDA found FEND offered for sale in the U.S. with claims it can mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says this makes it an unapproved new drug and a misbranded drug.

What FDA found

  1. FEND is an unapproved new drug—a drug FDA has not approved—because it is sold with claims to prevent or treat COVID-19.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. FEND is misbranded—labeled with misleading claims—because its website and social media say it is safe or effective for COVID-19.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company is prohibited from shipping FEND in interstate commerce while it is unapproved and misbranded.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that FEND can prevent, treat, or slow COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA asks the company to immediately stop selling any unapproved/unauthorized products for COVID-19 and, within 48 hours, email FDA describing the specific corrective steps, how it will prevent recurrence, and related documentation. FTC separately asks for certification within 48 hours that the unsubstantiated claims have ceased.

Who should pay attention

  • companies selling nasal sprays or hygiene devices with COVID-19 claims
  • retailers and online marketplaces listing unapproved COVID-19 products
  • marketing and regulatory teams reviewing disease claims on websites and social media

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk